<sub id="d1nvr"><font id="d1nvr"><dfn id="d1nvr"></dfn></font></sub>

    <address id="d1nvr"></address>

    <b id="d1nvr"><cite id="d1nvr"><ruby id="d1nvr"></ruby></cite></b><video id="d1nvr"></video>

    <form id="d1nvr"><var id="d1nvr"><address id="d1nvr"></address></var></form>

    <meter id="d1nvr"></meter>

    <form id="d1nvr"></form>

      CHAIRMAN'S STATEMENT
      2020 has been a challenging year, an unprecedented year. The impact from the outbreak of the novel coronavirus (“COVID-19”) was in ways we never had imagined.
      During the year under review, COVID-19 has negatively impacted our financial results and caused delay in ongoing clinical trial programmes. However, in these demanding times, leadership, team spirits and acting responsibly have become the most critical value to be resilient and allowed us to continue executing our plans.

      FINANCIAL PERFORMANCE
       
      For the year ended 31 December 2020, Essex Bio-Technology Limited (the “Company”, together with its subsidiaries, the “Group”) achieved a consolidated turnover of approximately HK$978.1 million, a decrease of 23.6% over the last year. The decrease is attributable to about 44.3% decrease in the first half of 2020 as the government implemented a series of control measures in a number of provinces and municipalities in the People’s Republic of China (the “PRC”) to curb the spread of COVID-19, which had significantly disrupted the clinical operations of hospitals in the PRC and had prevented non emergency patients visiting hospitals and outpatient clinics. However, as clinical operations of hospitals in the PRC have been largely resumed to normalcy in September 2020, the Group’s revenue has also been recovering to nearing the pre-COVID-19 level from the third quarter. The recovery had helped lower the decrease in revenue in the second half to approximately 6.2% as compared to the same period of last year.
       
      The Group’s turnover is primarily made up from the segments of Ophthalmology and Surgical (Wound care and healing). The core products that are of current growth driver under each segment are:
       

      1. Ophthalmology – Beifushu series (Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops), Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Xalatan® Eye Drops, Xalacom® Eye Drops and 適麗順® (Iodized Lecithin Capsules*); and
      2. Surgical (Wound care and healing) – Beifuji series (Beifuji spray, Beifuji lyophilised powder and Beifuxin gel), T-Bactum® (anti-microbial oral care product), Carisolv® dental caries removal gel and 伊血安顆粒 (Yi Xue An Granules*).

       
      The sectoral turnover of Ophthalmology and Surgical is approximately 42.9% and 57.1% of the Group’s turnover, respectively. The combined turnover of the Group’s flagship biologics, Beifushu series and Beifuji series, the basic fibroblast growth factor (bFGF) based biologic drugs, represented about 83.3% of the Group’s total turnover, of which Beifushu series and Beifuji series accounted for 27.1% and 56.2% of the Group’s turnover, respectively. The remaining 16.7% of the Group’s turnover is largely contributed from sales of Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Xalatan® Eye Drops, Xalacom® Eye Drops, 適麗順® (Iodized Lecithin Capsules*), T-Bactum® and 伊血安顆粒 (Yi Xue An Granules*), collectively.
       
      Ophthalmology segment contributed approximately HK$419.2 million to the Group’s turnover for the year ended 31 December 2020, representing a decrease of 26.1% as compared to last year. Surgical segment recorded a total turnover of approximately HK$558.9 million for the year ended 31 December 2020, representing a decrease of 21.5% as compared to last year. The decrease was attributed to the aforementioned impact of COVID-19.
       
      During the year under review, the Group achieved after-tax profit of approximately HK$218.9 million as compared to approximately HK$302.5 million in 2019, representing a decrease of 27.6% which was attributed o the aforementioned impact of COVID-19.
       
      As at 31 December 2020, the Group had cash and cash equivalents of approximately HK$599.8 million (31 December 2019: approximately HK$473.3 million).
       
      SIGNIFICANT BUSINESS DEVELOPMENT ACTIVITIES


      We are committed to pragmatically investing in new products and technologies to strengthen the Group’s product and research and development (“R&D”) pipeline as near to mid-term growth driver in ophthalmology and long-term plan for new therapeutics in oncology. During the year under review, investments in ophthalmic products and licensing of a molecule for use in oncology are outlined as follows:
       
      Investments in Ophthalmology

      On 4 June 2020, the Group entered into a framework agreement with 西藏林芝百盛藥業有限公司 (Tibet Linzhi Parkson Pharmaceutical Co., Ltd.*) in relation to the possible acquisition of all intellectual property rights relating to all technologies and process of product R&D and production of 適麗順® (Iodized Lecithin Capsules*) and other medicinal products in different forms in which iodized lecithin serves as an active pharmaceutical ingredient.
       
      On 15 October 2020, the Group entered into a co-development and exclusive license agreement (the “Co-Development License Agreement”) with Shanghai Henlius Biotech, Inc (“Henlius”). Pursuant to the Co- Development License Agreement, the Group has agreed to fund up to US$24.0 million i.e. 80% of the development costs of a pharmaceutical product that contains an anti-vascular endothelial growth factor (“anti-VEGF”) as a drug substance (the “Licensed Product”), which is intended for the treatment of exudative (wet) age-related macular degeneration (“wet-AMD”), being a bevacizumab biosimilar candidate. In return, the Group has obtained an exclusive license for the regulatory development, manufacture and commercialisation of the Licensed Product worldwide, subject to commercial sales milestone payment and royalties levied on net sales of the Licensed Product payable to Henlius. In the event that the Group grants a sub-license to a third party for commercialisation of the Licensed Product, the Group will share 20% of the relevant sublicensing revenue with Henlius.
       
      The filing by Henlius of clinical trial for recombinant anti-VEGF humanised monoclonal antibody ophthalmic injection HLX04-O for the treatment of wet-AMD has been approved by Therapeutic Goods Administration, Australia, and the phase 3 clinical trial is permitted to commence in Australia (CTN No. CT-2020-CTN-04843-1). Accordingly, a phase 3 clinical study with respect to the Licensed Product is intended and expected to be initiated in Australia in the near future.
       
      The Licensed Product can be used for treating wet-AMD, diabetic macular edema, macular edema caused by retinal vein occlusion and myopic choroidal neovascularisation. In accordance with the report of Frost & Sullivan, the estimated number of patients of these 4 categories is over 15.5 million in the PRC in 2019. Assuming each patient applies 4 doses in the first year of treatment and 2 to 3 doses in subsequent years, it is expected that the size of the potential market of the Licensed Product will be significant.
       
      Apart from the above investments, in 2018, the Group entered into a co-development agreement with Mitotech S.A. and Mitotech LLC for the United States Food and Drug Administration (“US FDA”) phase 3 clinical trial of an ophthalmic solution containing SkQ1 for dry eye disease. As disclosed in the announcement of the Company dated 24 February 2021, positive outcome was achieved during second phase 3 clinical trial (VISTA-2). The clinical trial study repeated statistically significant positive results on key predefined secondary end-point (Central Corneal Fluorescein Staining). The board of directors of the Company (the “Board”) is enthusiastic about the read-out of clearing of central staining of the cornea (defined as zero staining in central cornea), which reveals the potential of SkQ1 in addressing oxidative stress in dry eye diseases, and is looking forward to seeing the results of the third phase 3 clinical trial (VISTA-3) on the overall regulatory pathway towards the new drug application submission with the US FDA targeted by Mitotech S.A. to be made in the year of 2022 to 2023.
       
      Investment in Oncology
       
      On 28 August 2020, the Group entered into an intellectual property license agreement (the “IP License Agreement”) with 廣州康睿生物醫藥科技股份有限公司 (Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd.*) (“Kangrui”). Pursuant to the IP License Agreement, Kangrui granted to the Group an exclusive license to develop, manufacture, use or otherwise commercialise any therapeutic products incorporating the molecule initially developed by Kangrui for use in oncology (the “Molecule”).
       
      In line with the Group’s strategic development plans in oncology, the IP License Agreement presents a good opportunity for the Group to evaluate the suitability of developing and commercialising the Molecule in the field of therapeutic use and/or therapies in oncology.
       
      MARKET DEVELOPMENT
       
      Over the years, the Group has been relentlessly investing in establishing and strengthening its market access capability. As at 31 December 2020, the Group maintains a network of 43 regional sales offices in the PRC and a total number of about 1,290 sales and marketing representatives, out of which approximately 38% are on contract basis or from appointed agents.
       
      During the year under review, the Group’s therapeutic products are being prescribed in more than 9,000 hospitals and medical providers, coupled with approximately 2,000 pharmaceutical stores, which are mainly located in the major cities, provinces and county cities in the PRC.
       
      For achieving a sustainable traction on growth for currently marketed products as well as for near-term to midterm new products being commercialised, the Group initiated investments to improve its competitiveness and widen its customer base under the following plans:
       
      • Investing in clinical observation programmes for affirming additional clinical indications of its commercialised products;

      • Reaching out to market in lower-tier cities;

      • Cultivating pharmaceutical stores, where possible, as complementary sales channel; and

      • Building on-line platform for medical consultation and e-prescription for patients with chronic diseases under its healthtech initiative.
       
      During the year under review, the Group has initiated its market access expansion to Southeast Asian countries by setting up a base in Singapore.



      RESEARCH AND DEVELOPMENT
       
      During the year under review, the Group renewed its R&D’s vision, dedicated to science and innovation, with a mission to develop therapeutics that would meet unmet clinical and/or commercial needs. The Group concurrently kick-started a 5-year (2021 to 2025) R&D’s development plan to further strengthen its R&D capability and its position in ophthalmology.
       
      The Group's key R&D initiatives comprise of growth factor, antibody (i.e. mAb, bsAb, sdAb, scFv, ADC/ FDC, etc.), drug formulation know-how and Blow-Fill-Seal (“BFS”) platform. Growth factor, antibody and drug formulation know-how are used for the development of therapeutic drugs in ophthalmology, surgical (wound care and healing) and oncology, whereas BFS platform is a state-of-the-art manufacturing facility for producing preservative-free unit-dose drugs, in particular for ophthalmic drugs.
       
      As at 31 December 2020, there are 15 R&D programmes in the pre-clinical to clinical stage, out of which 4 ophthalmology programmes are in Investigational New Drug (“IND”)/Clinical/New Drug Application (“NDA”) stage. The 4 ophthalmology programmes listed below are targeted as mid-term growth driver.
       
      1. EB11-18136P: SkQ1 eye drops, second phase 3 clinical trial (US FDA) topline data released on 24 February 2021

      2. EB11-15120P: Azithromycin eye drops, pending phase 3 clinical trial results (National Medical Products Administration (“NMPA”) in the PRC)

      3. EB11-13108P: Moxifloxacin eye drops, NDA stage (NMPA in the PRC)

      4. EB12-20145P: Bevacizumab for wet-AMD, IND ready stage (global, US FDA, European Medicines Agency and NMPA in the PRC)
       
      During the year under review, the following programmes were completed with good success. The completed programmes would strengthen the currently marketed product portfolio, served as near-term growth driver.
       
      1. EB12-05100P (ophthalmology): Beifushu (FGF2) unit-dose eye drops, entered commercial stage (in the PRC)

      2. EB12-17133Z (dermatology): Beifuji (FGF2) increased dosage for external use, entered commercial stage (in the PRC)

      3. EB23-18235Y (stomatology): T-Bactum® (anti-microbial oral care product), entered commercial stage (in the PRC)
       
      As at the date of this report, the Group has obtained a total of 34 patent certificates or authorisation letters: 27 發明專利 (invention patents), 3 實用新型專利 (utility model patents) and 4 外觀專利 (design patents).

      To advance our pursuits of new therapeutics programme involving antibodies that, in particular, target in oncology and ophthalmology, a wholly-owned subsidiary, EssexBio Therapeutics Inc. (“EssexBio USA”), has been incorporated in the United States in March 2020. EssexBio USA is set up as the Group’s R&D centre and clinical trial management of the Group’s products in the United States. Being in the United States, EssexBio USA will continue to position the Group with better visibility for in and out licensing potential of technologies and products.
       
      PROSPECTS

      COVID-19 remains a major concern in 2021 globally. We continue to monitor the situation and will take appropriate actions to overcome any difficulty in this unforeseen circumstance. Barring the unforeseen circumstance, the Group remains focus on executing its plans and delivering progressive results.
       
      DIVIDEND

      To reward our valued shareholders, the Board is pleased to propose a final dividend of HK$0.05 (2019: HK$0.05) per ordinary share to be approved at the upcoming annual general meeting of the Company.
       
      APPRECIATION

      I would like to take this opportunity to express my sincere gratitude to all stakeholders, business associates and valued customers for the trust, support and cooperation accorded to us, and each and every member of the Group for their relentless efforts rendered in shaping the Group into being a progressive and promising pharmaceutical player.
       
      Ngiam Mia Je Patrick
      Chairman

      Hong Kong
      12 March 2021


      * For identification purpose only

      This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
      免费看男生裸体自慰_韩国公和熄2_黑帽门7分40视频_男同志FREEVOIDEOS免费